KARYOPHARM THERAPEUTICS INC's ticker is and the CUSIP is 48576UAA4. A total of 20 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $9,548,000 | -21.9% | 11,460,000 | -23.4% | 0.77% | -17.1% |
| Q4 2021 | $12,230,000 | +6.9% | 14,960,000 | 0.0% | 0.93% | -13.5% |
| Q3 2021 | $11,437,000 | -23.9% | 14,960,000 | -0.3% | 1.07% | -33.4% |
| Q2 2021 | $15,028,000 | +60.4% | 15,000,000 | +66.7% | 1.61% | +40.9% |
| Q1 2021 | $9,367,000 | – | 9,000,000 | – | 1.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| STEELHEAD PARTNERS LLC | 16,000,000 | $16,661,000 | 1.26% |
| Opti Capital Management, LP | 9,000,000 | $9,367,000 | 1.14% |
| Context Capital Management, LLC | 10,500 | $10,883,000 | 1.07% |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | 20,000,000 | $20,429,000 | 0.20% |
| AQR Arbitrage LLC | 4,100,000 | $4,249,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 25,000,000 | $25,538,000 | 0.13% |
| CAPSTONE INVESTMENT ADVISORS, LLC | 13,500,000 | $13,992,000 | 0.04% |
| LAZARD ASSET MANAGEMENT LLC | 22,500,000 | $23,319,000 | 0.03% |
| Citadel Advisors | 48,300,000 | $50,405,000 | 0.01% |
| MACKAY SHIELDS LLC | 93,000 | $96,000 | 0.00% |